Evidence map›Paper›PMID 37103081›Full record

SynthesisIn vivo (Athens, Greece)

Efficacy of Ascorbic Acid, Thiamine, and Hydrocortisone Combination Therapy: Meta-analysis of Randomized Controlled Trials.

Takahiro Kato, Tomohiro Mizuno, Masanori Nakanishi, Jeannie K Lee, Shigeki Yamada, Naotake Tsuboi, Kazuo Takahashi

Open access · diamondAbstract readMeta-Analysis
In one paragraph

Synthesis in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Takahiro KatoDepartment of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan.
Tomohiro MizunoDepartment of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan; tomohiro.mizuno@fujita-hu.ac.jp.
Masanori NakanishiDepartment of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan.
Jeannie K LeeDepartment of Pharmacy Practice & Science, University of Arizona R. Ken Coit College of Pharmacy, Tucson, AZ, U.S.A.
Shigeki YamadaDepartment of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan.
Naotake TsuboiDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan.
Kazuo TakahashiDepartment of Biomedical Molecular Sciences, Fujita Health University School of Medicine, Toyoake, Japan.
Fujita Health University · JPUniversity of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimSepsis is a life-threatening biological condition that induces systemic tissue and organ dysfunction and confers a high mortality risk. Although the use of hydrocortisone in combination with ascorbic acid and thiamine (HAT therapy) significantly reduced mortality from sepsis or septic shock in a previous study, it did not improve mortality in subsequent randomized controlled trials (RCTs). Therefore, no definitive conclusion has been established on the benefits of HAT therapy for sepsis or septic shock. We performed a meta-analysis to assess the treatment outcomes of HAT therapy in patients with sepsis or septic shock. PATIENTS AND

methodsWe searched databases (PubMed/MEDLINE, Embase, Scopus and Cochrane Library) for RCTs using the terms "ascorbic acid", "thiamine", "sepsis", "septic shock", and "RCT". The primary outcome of this meta-analysis was the mortality rate, and the secondary outcomes were the incidence of new-onset acute renal injury (AKI), intensive care unit (ICU) length of stay (ICU-LOS), change in the Sequential Organ Failure Assessment (SOFA) score within 72 hours, and duration of vasopressor use.

resultsNine RCTs were identified and included in the outcome evaluation. HAT therapy did not improve the 28-day and ICU mortality, new-onset AKI, ICU-LOS, or SOFA scores. However, HAT therapy significantly shortened the duration of vasopressor use.

conclusionHAT therapy did not improve mortality, the SOFA score, renal injury, or ICU-LOS. Further studies are needed to confirm whether it shortens the duration of vasopressor use.

Indexed as

Acute Kidney InjurySepsisShock, SepticAscorbic AcidHumansHydrocortisoneRandomized Controlled Trials as TopicThiamineAscorbic AcidHydrocortisoneThiamineHAT therapymortalitySepsisSOFA

Identifiers

PMID37103081
PMCPMC10188022
OpenAlexW4367174249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.